Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biotrial Says Will Continue To Cooperate As French Probe Manslaughter Angle in Phase I Case

Executive Summary

French prosecutors are beginning judicial proceedings into possible manslaughter following the Phase I trial tragedy in January this year, although CRO Biotrial says the move is "a normal decision" in a complex investigation.

You may also be interested in...

Biotrial Rejects French Phase I Inquiry Findings, Says Action Plan Already In Place

The French health ministry has given Biotrial, the CRO that ran the disastrous Phase I FAAH inhibitor study in Rennes, one month in which to draw up an action plan to ensure that the "major failings" seen in the trial "cannot happen again." If it fails to do so it may lose its authorization to conduct clinical trials.

French Police Search Drug Regulator's Premises Over Phase I FAAH Study

French regulator ANSM is under scrutiny following a visit by police investigating the tragic Phase I FAAH inhibitor study, and confirms that it carried out an "internal investigation" whose results have been passed to police and the social affairs inspectorate.

AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval

A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts